Search for lepton flavor violating decays of a heavy neutral particle in p-pbar collisions at root(s)=1.8 TeV

We report on a search for a high mass, narrow width particle that decays directly to e+mu, e+tau, or mu+tau. We use approximately 110 pb^-1 of data collected with the Collider Detector at Fermilab from 1992 to 1995. No evidence of lepton flavor violating decays is found. Limits are set on the production and decay of sneutrinos with R-parity violating interactions.Comment: Figure 2 fixed. Reference 4 fixed. Minor changes to tex

Clinical features and outcomes of elderly hospitalised patients with chronic obstructive pulmonary disease, heart failure or both

Background and objective: Chronic obstructive pulmonary disease (COPD) and heart failure (HF) mutually increase the risk of being present in the same patient, especially if older. Whether or not this coexistence may be associated with a worse prognosis is debated. Therefore, employing data derived from the REPOSI register, we evaluated the clinical features and outcomes in a population of elderly patients admitted to internal medicine wards and having COPD, HF or COPD + HF. Methods: We measured socio-demographic and anthropometric characteristics, severity and prevalence of comorbidities, clinical and laboratory features during hospitalization, mood disorders, functional independence, drug prescriptions and discharge destination. The primary study outcome was the risk of death. Results: We considered 2,343 elderly hospitalized patients (median age 81 years), of whom 1,154 (49%) had COPD, 813 (35%) HF, and 376 (16%) COPD + HF. Patients with COPD + HF had different characteristics than those with COPD or HF, such as a higher prevalence of previous hospitalizations, comorbidities (especially chronic kidney disease), higher respiratory rate at admission and number of prescribed drugs. Patients with COPD + HF (hazard ratio HR 1.74, 95% confidence intervals CI 1.16-2.61) and patients with dementia (HR 1.75, 95% CI 1.06-2.90) had a higher risk of death at one year. The Kaplan-Meier curves showed a higher mortality risk in the group of patients with COPD + HF for all causes (p = 0.010), respiratory causes (p = 0.006), cardiovascular causes (p = 0.046) and respiratory plus cardiovascular causes (p = 0.009). Conclusion: In this real-life cohort of hospitalized elderly patients, the coexistence of COPD and HF significantly worsened prognosis at one year. This finding may help to better define the care needs of this population

Momentum distribution of charged particles in jets in dijet events in p(p)over-bar collisions at root s=1.8 TeV and comparisons to perturbative QCD predictions

Inclusive momentum distributions of charged particles in restricted cones around jet axes were measured in dijet events with invariant dijet masses in the range 80 to 600 GeV/c(2). Events were produced at the Fermilab Tevatron in p (p) over bar collisions with a center of mass energy of 1.8 TeV and recorded by the Collider Detector at Fermilab. The results were compared to perturbative QCD calculations carried out in the framework of the modified leading log approximation (MLLA) and assuming local parton-hadron duality. It was shown that the data follow theoretical predictions quite well over the whole range of the jet energies included in this analysis. We extracted the MLLA cutoff scale Q(eff) and found a value of 230+/-40 MeV. The theoretical prediction of E(jet)sin theta(c) scaling, where theta(c) is the cone opening angle, was experimentally observed for the first time. From the MLLA fits to the data, two more parameters were extracted: the ratio of parton multiplicities in gluon and quark jets, r=N-partons(g-jet)/N-partons(q-jet)=1.9+/-0.5, and the ratio of the number of charged hadrons to the number of predicted partons in a jet, K-LPHD(charged)=N-hadrons(charged)/N-partons=0.56+/-0.10

Search for a W(') boson decaying to a top and bottom quark pair in 1.8 TeV p(p)over-bar collisions

We report the results of a search for a W(') boson produced in p (p) over bar collisions at a center-of-mass energy of 1.8 TeV using a 106 pb(-1) data sample recorded by the Collider Detector at Fermilab. We observe no significant excess of events above background for a W(') boson decaying to a top and bottom quark pair. In a model where this boson would mediate interactions involving a massive right-handed neutrino (nu(R)) and have standard model strength couplings, we use these data to exclude a W(') boson with mass between 225 and 536 GeV/c(2) at 95\% confidence level for M(W)(')>M(nuR) and between 225 and 566 GeV/c(2) at 95\% confidence level for M(W)(')<M(nuR)

Search for associated production of Upsilon and vector boson in p(p)over-bar collisions at root(s)over-bar=1.8 TeV

We present a search for associated production of the Y(1S) and a vector boson in 83 pb(-1) of p (p) over bar collisions at roots=1.8 TeV collected by the CDF experiment in 1994-1995. We find no evidence of the searched signal in the data, and set upper limits to the production cross sections

Search for a W(') boson decaying to a top and bottom quark pair in 1.8 TeV p(p)over-bar collisions

We report the results of a search for a W(') boson produced in p (p) over bar collisions at a center-of-mass energy of 1.8 TeV using a 106 pb(-1) data sample recorded by the Collider Detector at Fermilab. We observe no significant excess of events above background for a W(') boson decaying to a top and bottom quark pair. In a model where this boson would mediate interactions involving a massive right-handed neutrino (nu(R)) and have standard model strength couplings, we use these data to exclude a W(') boson with mass between 225 and 536 GeV/c(2) at 95% confidence level for M(W)(')>M(nuR) and between 225 and 566 GeV/c(2) at 95% confidence level for M(W)(')<M(nuR)

Search for the supersymmetric partner of the top quark in dilepton events from p(p)over-bar collisions at root s=1.8 TeV

We have searched for the supersymmetric partner of the top quark (stop) in 107 pb^{-1} of p-pbar collisions at \sqrt{s}= 1.8 TeV collected by the Collider Detector at Fermilab (CDF). Within the framework of the Minimal Supersymmetric extension of the Standard Model (MSSM) each of the pair-produced stops is assumed to decay into a lepton, bottom quark and supersymmetric neutrino. Such a scenario would give rise to events with two leptons, two hadronic jets, and a substantial imbalance of transverse energy. No evidence of such a stop signal has been found. We calculate a 95% confidence level (C.L.) upper limit on the stop production cross section, which excludes stop masses in the region (80<m_{\stop}<135 GeV/c^2) in the mass plane of stop versus sneutrino.Comment: 7 pages, 5 figures. Submitted to Physical Review Letter

Central pseudorapidity gaps in events with a leading antiproton at the Fermilab tevatron (p)over-barp collider

We report a measurement of the fraction of events with a large pseudorapidity gap Deltaeta within the pseudorapidity region available to the proton dissociation products X in (p) over bar +p--&gt;(p) over bar +X. For a final state (p) over bar of fractional momentum loss xi((p) over bar) and 4-momentum transfer squared t((p) over bar) within 0.063 is found to be 0.246+/-0.001 (stat)+/-0.042 (syst) [0.184+/-0.001 (stat)+/-0.043 (syst)]. Our results are compared with gap fractions measured in minimum bias (p) over barp collisions and with theoretical expectations

Efficacy of Long-Term Treatment of Autosomal Recessive Hypercholesterolemia With Lomitapide: A Subanalysis of the Pan-European Lomitapide Study

Background and aim: Autosomal recessive hypercholesterolemia (ARH) is a rare autosomal recessive disorder of low-density lipoprotein (LDL) metabolism caused by pathogenic variants in the LDLRAP1 gene. Like homozygous familial hypercholesterolemia, ARH is resistant to conventional LDL-lowering medications and causes a high risk of atherosclerotic cardiovascular diseases (ASCVDs) and aortic valve stenosis. Lomitapide is emerging as an efficacious therapy in classical HoFH, but few data are available for ARH.Results: This is a subanalysis carried out on nine ARH patients included in the Pan-European Lomitapide Study. The age at starting lomitapide was 46 (interquartile range (IQR), 39.0-65.5) years, with a median treatment duration of 31.0 (IQR 14.0-40.5) months. At baseline, four (44.4%) patients had hypertension, one (11.1%) had diabetes mellitus, two (22.2%) were active smokers, and five (55.5%) reported ASCVD. The baseline LDL-C was 257.0 (IQR, 165.3-309.2) mg/dL. All patients were on statins plus ezetimibe, three were receiving Lipoprotein apheresis (LA), and one was also receiving proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i). The addition of lomitapide (mean dose, 10 mg) resulted in the achievement of a median on-treatment LDL-C of 101.7 mg/dL (IQR, 71.3-138.3; 60.4% reduction from baseline), with a best LDL-C value of 68.0 mg/dL (IQR, 43.7-86.7; 73.5% reduction from baseline). During follow-up, one patient stopped both PCSK9i and LA. Recurrence of ASCVD events was reported in one patient. The median on-treatment aspartate transaminase and alanine transaminase values were 31.1 (IQR, 22.6-48.3) U/L and 31.1 (IQR, 27.2-53.8) U/L, respectively. Among six ARH patients with available fibroscan examination, liver stiffness values recorded at the last visit were within the normal range (median, 4.7 KPa; IQR, 3.6-5.3 KPa).Conclusion: Lomitapide is effective and safe in ARH therapy as well as in classical HoFH